Immunocore (NASDAQ:IMCR) CEO Sells $371,183.90 in Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) CEO Bahija Jallal sold 11,474 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares in the company, valued at approximately $399,296.05. This represents a 48.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Immunocore Trading Up 2.0%

Shares of IMCR stock traded up $0.66 on Thursday, reaching $33.17. 392,220 shares of the company’s stock were exchanged, compared to its average volume of 465,558. The company’s fifty day simple moving average is $33.94 and its 200 day simple moving average is $34.31. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.71. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.68 billion, a PE ratio of -58.19 and a beta of 0.78.

Analyst Ratings Changes

IMCR has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, February 4th. Morgan Stanley lifted their price objective on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Finally, UBS Group set a $55.00 target price on shares of Immunocore and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. Primecap Management Co. CA increased its position in Immunocore by 5.5% during the 4th quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock valued at $137,517,000 after purchasing an additional 207,320 shares during the period. Bellevue Group AG boosted its stake in shares of Immunocore by 14.5% during the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares in the last quarter. Tang Capital Management LLC increased its holdings in Immunocore by 14.0% during the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after buying an additional 322,930 shares during the period. Millennium Management LLC increased its holdings in Immunocore by 334.3% during the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after buying an additional 974,463 shares during the period. Finally, Armistice Capital LLC raised its stake in Immunocore by 33.3% in the fourth quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock worth $38,112,000 after buying an additional 274,000 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.